Johnson & Johnson has announced new data from Cohort 2 of Phase 2b SunRISe-1, indicating that TAR-200 monotherapy achieves a high disease-free survival rate exceeding 80 percent in BCG-unresponsive, high-risk papillary non-muscle invasive bladder cancer (NMIBC). This development aims to fundamentally change the treatment approach for this type of bladder cancer. Meanwhile, ImmunityBio is also focusing on defense strategies in this area. TAR-200 has shown prolonged disease-free survival in BCG-unresponsive, papillary high-risk NMIBC cases.
— new from Fierce Pharma
